Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer

Seminars in Oncology Nursing

Volumn 19, Issue SUPPL. 1, 2003, Pages 19-39

  Edwards, Susan J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANALGESIC AGENT; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DIPHENOXYLATE; DOLASETRON MESILATE; DOXORUBICIN; DRONABINOL; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANISETRON; HALOPERIDOL; KAOLIN PECTIN; LAXATIVE; LOPERAMIDE; LORAZEPAM; METOCLOPRAMIDE; OCTREOTIDE; ONDANSETRON; OPIATE; PACLITAXEL; PROCHLORPERAZINE; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN; THIETHYLPERAZINE; TOPOTECAN; UNINDEXED DRUG; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ACUPUNCTURE; ALOPECIA; ANAMNESIS; ANEMIA; ASTHENIA; BACKACHE; BONE MARROW SUPPRESSION; CANCER PAIN; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL FEATURE; COGNITIVE DEFECT; CONSTIPATION; DELIRIUM; DIARRHEA; DIETARY INTAKE; DISEASE SEVERITY; DRUG DOSE REDUCTION; EXERCISE; FATIGUE; FLUID INTAKE; HALLUCINATION; HAND FOOT SYNDROME; HEALTH EDUCATION; HUMAN; HYPERSENSITIVITY REACTION; INTESTINE OBSTRUCTION; MASSAGE; MOUTH ULCER; MOUTHWASH; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PROTEIN INTAKE; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT WITHDRAWAL; VITAMIN SUPPLEMENTATION; VOMITING; CHEMICALLY INDUCED DISORDER; FEMALE; GASTROINTESTINAL DISEASE; METHODOLOGY; NURSING; NURSING ASSESSMENT; ONCOLOGY NURSING; OVARY TUMOR; PSYCHOLOGICAL ASPECT; TUMOR RECURRENCE;

ALOPECIA; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; NEOPLASM RECURRENCE, LOCAL; NURSING ASSESSMENT; ONCOLOGIC NURSING; OVARIAN NEOPLASMS;

EID: 0142089734     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-2081(03)00059-7     Document Type: Article

References (68)

1. Ozols RF: Future directions in the treatment of ovarian cancer. Semin Oncol 29:32-42, 2002 (suppl 1)
2. Alberts DS: Treatment of refractory and recurrent ovarian cancer. Semin Oncol 26:8-14, 1999 (suppl 1)
3. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001
4. Markman M, Rothrnan R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
5. Bookman MA, Malmstrom H, Bolis G, et al: Topotecan for the treatment of advanced epithelial ovarian cancer: An openlabel phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16:3345-2252, 1998
6. ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
7. Ozols RF: Update on the management of ovarian cancer. Cancer J 8:S22-S30, 2002 (suppl 1)
8. Cantu MG, Buda A, Parma G, et al: Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20:1232-1237, 2002
9. Bristol-Myers Squibb. Prescribing information for Paraplatin (carboplatin for injection). June 2001. Available at: http://www.bms.com/medicines/data/. (accessed September 9, 2002)
10. Bristol-Myers Squibb. Prescribing information for Platinol-AQ (cisplatin injection). October 1999. Available at: http://www.bms.com/medicines/data/. (accessed September 9, 2002)
11. Bristol-Myers Squibb. Prescribing information for Taxol (paclitaxel) injection. July 2000. Available at: http://www.bms.com/medicines/data/. (accessed September 9, 2002)
12. Ortho Biotech Products, LP. Prescribing information for Doxil (doxorubicin HCl liposome injection). September 2001. Available at: http://www.doxil.com. (accessed September 9, 2002)
13. GlaxoSmithKline. Prescribing information for Hycamtin (topotecan HCl). November 2001. Available at: http://www.us.gsk.com/products/assets/us_hycamtin. pdf. (accessed September 9, 2002)
14. MGI Pharma. Prescribing information for Hexalen (Altretamine) capsules. January 2001. Available at: http://www.mgipharma.com/index.htm. (accessed September 18, 2002)
15. AstraZeneca. Professional information brochure for Nolvadex (tamoxifen citrate). May 2002. Available at: http://www.astrazeneca-us.com/pi/Nolvadex.pdf. (accessed September 9, 2002)
16. Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 18:106-115, 2000
17. Rose PG, Blessing JA, Mayer AR, et al: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 16:405-410, 1998
18. Shapiro JD, Millward MJ, Rischin D, et al: Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 63:89-93, 1996
19. National Comprehensive Cancer Network. Cancer and treatment-related anemia. Clinical practice guidelines in oncology v. 1. 2003. Available at: http://www.nccn.org/physician_gls/index.html. (accessed April 16, 2003)
20. Dean GE, Stahl C: Increasing the visibility of patient fatigue. Semin Oncol Nurs 18:20-27, 2002
21. Wells JN, Fedric T: Helping patients manage cancer-related fatigue. Home Health Nurse 19:486-493, 2001
22. Carelle N, Piotto E, Bellanger A, et al: Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95:155-163, 2002
23. Fabian CJ, Molina R, Slavik M, et al: Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 8:57-63, 1990
24. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and American Society of Hematology. J Clin Oncol 20:4083-4107, 2002
25. Nail LM: Fatigue in patients with cancer. Oncol Nurs Forum 29:537-544, 2002
26. Munstedt K, Manthey N, Sachsse S, et al: Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer 5:139-143, 1997
27. McGarvey EL, Baum LD, Pinkerton RC, et al: Psychological sequelae and alopecia among women with cancer. Cancer Pract 9:283-289, 2001
28. Brown KA, Esper P, Kelleher LO, et al: Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. Pittsburgh, PA, Oncology Nursing Society, 2001
29. National Comprehensive Cancer Network: The Complete Library of Practice Guidelines in Oncology. Rockledge, PA, National Comprehensive Cancer Network, 2002
30. Bender CM, McDaniel RW, Murphy-Ende K, et al: Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 6:94-102, 2002
31. Rhodes VA, McDaniel RW: The Index of Nausea, Vomiting, and Retching: A new format of the Index of Nausea and Vomiting. Oncol Nurs Forum 26:889-894, 1999
32. Larrison EH: Management of side effects in patients with recurrent ovarian cancer. Semin Oncol 26:15-31, 1999 (suppl 1)
33. National Cancer Institute: Eating Hints for Cancer Patients Before, During & After Treatment. NIH Publication No. 01-2079. Bethesda, MD, National Cancer Institute, 1997
34. Cope DG: Management of chemotherapy-induced diarrhea and constipation. Nurs Clin North Am 36:695-707, 2001
35. Randall TC, Rubin SC: Management of intestinal obstruction in the patient with ovarian cancer. Oncology (Huntingt) 14:1159-1163, 2000
36. Kostler WJ, Hejna M, Wenzel C, et al: Oral mucositis complicating chemotherapy and/or radiotherapy: Options for prevention and treatment. CA Cancer J Clin 51:290-315, 2001
37. Dodd MJ, Miaskowski C, Dibble SL, et al: Factors influencing oral mucositis in patients receiving chemotherapy. Cancer Pract 8:291-297, 2000
38. Wojtaszek C: Management of chemotherapy-induced stomatitis. Clin J Oncol Nurs 4:263-270, 2000
39. Uziely B, Jeffers S, Isacson R, et al: Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785, 1995
40. Miller M, Kearney N: Oral care for patients with cancer: A review of the literature. Cancer Nurs 24:241-254, 2001
41. Dose AM: The symptom experience of mucositis, stomatitis, and xerostomia. Semin Oncol Nurs 11:248-255, 1995
42. Safra T, Groshen S, Jeffers S, et al: Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: Analysis of toxicities and predictors of outcome. Cancer 91:90-100, 2001
43. Camp-Sorrell D: Chemotherapy: Toxicity management, in Yarbro CH, Frogge MH, Goodman M, et al (eds): Cancer Nursing Principles and Practice (ed 5). Sudbury, MA, Jones and Bartlett, 2000, pp 444-486
44. Kennedy L, Diamond J: Assessment and management of chemotherapy-induced mucositis in children. J Pediatr Oncol Nurs 14:164-174, 1997
45. Sweeney CW: Understanding peripheral neuropathy in patients with cancer: Background and patient assessment. Clin J Oncol Nurs 6:163-166, 2002
46. Almadrones LA, Arcot R: Patient guide to peripheral neuropathy. Oncol Nurs Forum 26:1359-1360, 1999
47. Nagore E, Insa A, Sanmartín O: Antineoplastic therapy-induced palmar-plantar erythrodysesthesia ('hand- foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 1:225-234, 2000
48. Pike K: Hand-foot syndrome. Oncol Nurs Forum 28:1519-1520, 2001
49. Gabizon AA, Muggia FM: Initial clinical evaluation of pegylated-liposomal doxorubicin in solid tumors, in Woodle MC, Storm G, (eds): Long Circulating Liposomes: Old Drugs, New Therapeutics. New York, NY, Springer-Verlag and Landes Bioscience, 1998, 165-174
50. Colbern GT, Musterer R, Killer AJ, et al: Treatment of palmar-plantar erythrodysthesia with pyroxidine or ergotamine: Effect on efficacy of Doxil in Lewis lung carcinoma. Proc Am Soc Clin Oncol 17:238a, 1998 (abstr 913)
51. Labovich TM: Acute hypersensitivity reactions to chemotherapy. Semin Oncol Nurs 15:222-231, 1999
52. Myers JS: Hypersensitivity reaction to paclitaxel: Nursing interventions. Clin J Oncol Nurs 4:161-163, 2000
53. Cormio G, Di Vagno G, Melilli GA, et al: Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. J Chemother 11:407-409, 1999
54. Robinson JB, Singh D, Bodurka-Bevers DC, et al: Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 82:550-558, 2001
55. Markman M, Kennedy A, Webster K, et al: Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17:1141-1145, 1999
56. Zanotti KM, Rybicki LA, Kennedy AW, et al: Carboplatin skin testing: A skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19:3126-3129, 2001
57. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997
58. Rivera E, Valero V, Syrewicz L, et al: Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 19:1716-1722, 2001
59. Wigler N, O'Brien M, Rosso R, et al: Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (CAELYX/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Poster presented at: Annual Meeting of the American Society of Clinical Oncology, May 12-15, 2001, San Francisco, CA
60. 2. Ann Oncol 11:1029-1033, 2000
61. Armstrong D, O'Reilly S: Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist 3:4-10, 1998
62. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 91:1616-1634, 1999
63. Anastasia PJ: Nursing considerations for managing topotecan-related hematologic side effects. Clin J Oncol Nurs 5:9-13, 2001
64. American Society of Clinical Oncology. Use of hematopoietic colony-stimulating factors. Evidence-based, practice guidelines. 2000. Available at: http://www.asco.org/. (accessed December 17, 2002)
65. Swenson CJ: Ethical issues in pain management. Semin Oncol Nurs 18:135-142, 2002
66. Yates PM, Edwards HE, Nash RE, et al: Barriers to effective cancer pain management: A survey of hospitalized cancer patients in Australia. J Pain Symptom Manage 23:393-405, 2002
67. Vallerand AH, Polomano RC: The relationship of gender to pain. Pain Manag Nurs 1:8-15, 2000
68. Juarez G, Ferrell B, Borneman T: Cultural considerations in education for cancer pain management. J Cancer Educ 14:168-173, 1999